Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, and Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts (M.K., S.K., T.P., C.R.).
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts (C.S.M., T.C.).
Ann Intern Med. 2024 Aug;177(8):1078-1088. doi: 10.7326/M24-0199. Epub 2024 Jul 16.
Many hospitals have scaled back measures to prevent nosocomial SARS-CoV-2 infection given large decreases in the morbidity and mortality of SARS-CoV-2 infections for most people. Little is known, however, about the morbidity and mortality of nosocomial SARS-CoV-2 infections for hospitalized patients in the Omicron era.
To estimate the effect of nosocomial SARS-CoV-2 infection on hospitalized patients' outcomes during the pre-Omicron and Omicron periods.
Retrospective matched cohort study.
5 acute care hospitals in Massachusetts, December 2020 to April 2023.
Adults testing positive for SARS-CoV-2 on or after hospital day 5, after negative SARS-CoV-2 test results on admission and on hospital day 3, were matched to control participants by hospital, service, time period, days since admission, and propensity scores that incorporated demographics, comorbid conditions, vaccination status, primary diagnosis category, vital signs, and laboratory test values.
Primary outcomes were hospital mortality and time to discharge. Secondary outcomes were intensive care unit (ICU) admission, need for advanced oxygen support, discharge destination, hospital-free days, and 30-day readmissions.
There were 274 cases of hospital-onset SARS-CoV-2 infection during the pre-Omicron period and 1037 cases during the Omicron period (0.17 vs. 0.49 cases per 100 admissions). Patients with hospital-onset SARS-CoV-2 infection were older and had more comorbid conditions than those without. During the pre-Omicron period, hospital-onset SARS-CoV-2 infection was associated with increased risk for ICU admission, increased need for high-flow oxygen, longer time to discharge (median difference, 4.7 days [95% CI, 2.9 to 6.6 days]), and higher mortality (risk ratio, 2.0 [CI, 1.1 to 3.8]) versus matched control participants. During the Omicron period, hospital-onset SARS-CoV-2 infection remained associated with increased risk for ICU admission and increased time to discharge (median difference, 4.2 days [CI, 3.6 to 5.0 days]). The association with increased hospital mortality was attenuated but still significant (risk ratio, 1.6 [CI, 1.2 to 2.3]).
Residual confounding may be present.
Hospital-onset SARS-CoV-2 infection during the Omicron period remains associated with increased morbidity and mortality.
Harvard Medical School Department of Population Medicine.
由于大多数人感染 SARS-CoV-2 的发病率和死亡率大幅下降,许多医院已减少了预防医院内 SARS-CoV-2 感染的措施。然而,关于奥密克戎时代住院患者医院内 SARS-CoV-2 感染的发病率和死亡率知之甚少。
估计奥密克戎前和奥密克戎期间医院内 SARS-CoV-2 感染对住院患者结局的影响。
回顾性匹配队列研究。
马萨诸塞州的 5 家急性护理医院,时间为 2020 年 12 月至 2023 年 4 月。
入院后第 5 天及入院时、第 3 天 SARS-CoV-2 检测结果为阴性后检测出 SARS-CoV-2 阳性的患者,与通过医院、服务、时间段、入院天数和包含人口统计学、合并症、疫苗接种状态、主要诊断类别、生命体征和实验室检查值的倾向评分进行匹配的对照组患者进行匹配。
主要结局是住院死亡率和出院时间。次要结局是 ICU 入院、需要高级氧气支持、出院去向、无住院天数和 30 天再入院。
在奥密克戎前期间发生了 274 例医院获得性 SARS-CoV-2 感染,而在奥密克戎期间发生了 1037 例(每 100 例入院分别为 0.17 例和 0.49 例)。与未发生医院获得性 SARS-CoV-2 感染的患者相比,发生医院获得性 SARS-CoV-2 感染的患者年龄更大,合并症更多。在奥密克戎前期间,医院获得性 SARS-CoV-2 感染与 ICU 入院风险增加、对高流量氧气需求增加、出院时间延长(中位数差异为 4.7 天[95%CI,2.9 至 6.6 天])和死亡率升高(风险比,2.0[CI,1.1 至 3.8])相关。在奥密克戎期间,医院获得性 SARS-CoV-2 感染仍然与 ICU 入院风险增加和出院时间延长相关(中位数差异为 4.2 天[CI,3.6 至 5.0 天])。与住院死亡率升高相关的关联减弱但仍有统计学意义(风险比,1.6[CI,1.2 至 2.3])。
可能存在残余混杂。
奥密克戎期间医院获得性 SARS-CoV-2 感染仍然与发病率和死亡率增加相关。
哈佛医学院人口医学系。